meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
5
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population
5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant
1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative
1
mNSCLC - L2 - PDL1 positive
7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population
1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population
1
squamous - mNSCLC - L2 - PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)
pembrolizumab (2mg/kg)
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs docetaxel
vs Standard of Care (SoC)
All patients
Age < 65y (younger)
Age > 65y
Age > 75y (older)
Asian type
cell type, non squamous cell
cell type, squamous cell
ECOG 0
ECOG 1
Gender, female
Gender, male
PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC)
PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC )
smoker (current or former)
smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
deaths (OS)
mNSCLC - L2 - PDL1 positive
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - PDL1 positive
versus docetaxel
avelumab alone vs. docetaxel
1
certainty unassessable
-9%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open